巴尔多克索隆甲基触发了心肌细胞中的铁
Hongmin Li1, Mengting Hong1, Yikun Liu1
1Advanced Institute for Medical Sciences, Dalian Medical University, Dalian, China.
Human & experimental toxicology
|November 27, 2025
概括
巴尔多克索隆甲基 (Bardo) 激活了Nrf2通路,但在心肌细胞中诱导铁亡,一种细胞死亡形式. 这一发现可能解释了Bardo在糖尿病病的临床试验中观察到的心血管并发症.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 巴多克索隆甲基 (Bardo) 激活了Keap1-Nrf2通路,显示出糖尿病病 (DKD) 的前景.
- 然而,由于心血管并发症,临床试验被停止,需要对Bardo的心脏毒性进行调查.
研究的目的:
- 为了阐明巴多克索隆甲基诱导心肌细胞损伤的机制.
- 为了确定巴多诱导的细胞死亡是否涉及铁亡,细胞亡或亡.
主要方法:
- 人类AC16心肌细胞用Bardo.com进行治疗.
- 评估了Nrf2激活,抗氧化剂表达 (HO-1,NQO1) 和细胞活力.
- 使用了铁亡,亡和亡抑制剂.
- 测量了氧化应激,脂质过氧化和线粒体功能的标志物.
主要成果:
- 巴多诱导了剂量依赖的Nrf2激活和心肌细胞死亡.
- 细胞死亡被铁灭抑制剂缓解,而不是其他药物.
- 巴尔多降低了铁灭调节剂 (GPX4,SLC7A11) 和增加了氧化应激标志物 (ROS,MDA,铁离子).
- 线粒体超结构显示出与铁亡相一致的迹象.
结论:
- 巴尔多克索隆甲基诱导心肌细胞中的铁亡.
- 这种铁亡机制可能是临床研究中观察到的心脏毒性作用的基础.
- 这些发现强调了了解药物诱导的细胞死亡途径的重要性.
相关概念视频
Necrosis
6.2K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
6.2K
Cardiomyopathy III: Hypertrophic Cardiomyopathy
374
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
374
Cardiomyopathy II: Dilated Cardiomyopathy
447
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
447
Cardiomyopathy IV: Restrictive Cardiomyopathy
431
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
431
Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K


